Currently Viewing:
Newsroom
Currently Reading
CRISPR-Gene Editing Technology Successfully Treated Lethal Lung Disease in Animal Models
April 20, 2019 – Samantha DiGrande
Study Finds Patients Misdiagnosed With MS Increases Morbidity, Healthcare Costs
April 19, 2019 – Samantha DiGrande
Sensor-based Algorithm Detects Patient Response to Parkinson Therapies
April 19, 2019 – Samantha DiGrande
Analyzing the Scent of Parkinson Disease Could Lead to Diagnostic Tool
April 19, 2019 – Wallace Stephens
This Week in Managed Care: April 19, 2019
April 19, 2019
ctDNA Can Detect MRD and Early Cancer Recurrence in Colorectal Cancer
April 19, 2019 – Laura Joszt
5 Findings From the April 2019 Issue of AJMC®
April 19, 2019 – Christina Mattina
What We're Reading: Long-Term Care Benefits; Predicting Obesity; Montana Reauthorizes Medicaid Expansion
April 19, 2019 – AJMC Staff
AJMC® in the Press, April 19, 2019
April 19, 2019 – AJMC Staff

Representatives Probe CMS for Further Detail on New CAR-T Therapy Payment Agreement

Christina Mattina
After CMS and Novartis devised an outcomes-based payment approach for the new chimeric antigen receptor (CAR)-T treatment tisagenlecleucel (Kymriah), a group of representatives are requesting more information on the specifics of the agreement.
After CMS and Novartis devised an outcomes-based payment approach for the new chimeric antigen receptor (CAR)-T treatment tisagenlecleucel (Kymriah), a group of representatives are requesting more information on the specifics of the agreement.

“As members strongly concerned with both rising prescription drug prices and the need to protect taxpayer access to therapies developed with public funding, we are watching closely the discussion around pricing for this treatment,” the letter to CMS administrator Seema Verma read. It was signed by a group of 9 Democratic members of the House of Representatives.

Novartis had first trumpeted the “groundbreaking collaboration” with CMS in its press release announcing the FDA’s approval of Kymriah. It indicated that pricing would be based on indications and outcomes, and that CMS would only pay for the immunotherapy treatment if the approved patients, pediatric and young adults with acute lymphoblastic leukemia, respond to Kymriah within their first month of therapy.

The representatives acknowledged that Kymriah, the first CAR-T therapy approved in the United States, “is a promising treatment that may benefit cancer patients,” but noted that it will only be effective if patients in need are able to afford it, considering the estimated $475,000 price tag. They also cited concerns about the $200 million in taxpayer funding used to finance the therapy’s development.

The letter included 14 questions for Verma on how CMS developed the outcomes-based payment equation for Kymriah. It asked for an explanation of payment mechanisms, details on data collection, and estimates on the number of patients who would be eligible, as well as how exactly a successful response would be defined. There were also questions about whether any of the CMS political appointees who had developed the agreement had ever worked for Novartis or elsewhere in the pharmaceutical industry.

CAR-T therapy is individualized by genetically modifying each patient’s T cells to include the CAR gene, then infusing them back into the patient, allowing the cells to target and kill leukemia cells. This customization costs around $20,000 per patient, but that price may decline as production is ramped up, according to Carl June, MD, a CAR-T researcher quoted in the letter. Considering this estimate, the representatives asked Verma how Novartis’ profit margin equates to a fair deal for taxpayers.

“We look forward to the opportunity to learn more about how CMS established this outcomes-based payment agreement and how it will be enacted,” the letter concluded. “We look forward to your reply and your continued engagement as the conversation around outcomes-based pricing moves forward.”

A CMS statement on the payment arrangement released at the time of Kymriah’s approval indicated its enthusiasm for novel payment models like outcomes-based pricing, particularly for innovative but costly therapies like CAR-T treatment, but did not provide further details on the Novartis agreement.

“Improving payment arrangements is a critical step towards fulfilling President Trump’s promise to lower the cost of drugs,” Verma said in the statement.

Two of the representatives who signed the letter, Peter Welch, D-Vermont, and Elijah Cummings, D-Maryland, met with President Donald Trump in March to discuss the high cost of prescription drugs. Cummings praised the president for being “aware of the problem” and “enthusiastic” about solutions like allowing Medicare to negotiate prices.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up